孕前及妊娠早期二甲双胍对多囊卵巢综合征女性妊娠结局的影响:系统综述与Meta分析
该系统综述与Meta分析纳入12项可信的随机对照试验(涉及1708名多囊卵巢综合征女性),评估孕前开始并持续至妊娠早期使用二甲双胍对妊娠结局的影响。结果显示,与安慰剂或不治疗相比,持续使用二甲双胍至妊娠早期者临床妊娠率升高(OR 1.57,95%CI 1.11-2.23),流产可能减少(OR 0.64,95%CI 0.32-1.25),活产可能增加(OR 1.24,95%CI 0.59-2.61)。间接比较显示持续使用较阳性妊娠试验后停药有更优趋势。
要点
- 孕前开始并持续至妊娠早期使用二甲双胍者临床妊娠率高于安慰剂或不治疗者(OR 1.57,95%CI 1.11-2.23)。
- 持续使用二甲双胍者流产风险可能降低(OR 0.64,95%CI 0.32-1.25),活产可能增加(OR 1.24,95%CI 0.59-2.61)。
- 阳性妊娠试验后即停用二甲双胍者临床妊娠率升高(OR 1.35,95%CI 1.01-1.80),但流产率有升高迹象(OR 1.46,95%CI 0.73-2.90)。
核心结论
- 持续使用二甲双胍至妊娠早期可能降低多囊卵巢综合征女性的流产风险并提高活产率。
- 持续使用二甲双胍似乎比阳性妊娠试验后停药具有更大的临床获益。
- 需要进一步的高质量研究。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase和Cochrane对照试验中心注册库,从建库至2024年8月1日。
- 纳入孕前开始并至少持续至阳性妊娠试验的二甲双胍随机对照试验,对照为安慰剂或不治疗,对象为多囊卵巢综合征女性。
- 共纳入12项可信研究,涉及1708名女性,所有研究质量分级为低至中等。
- 使用Cochrane随机试验偏倚风险工具(RoB 2)和推荐分级的评估、制定与评价(GRADE)方法评估质量。
- 使用Bucher技术对所有关键结局进行二甲双胍治疗时机的间接比较。
主要发现
- 与安慰剂或不治疗相比,孕前开始并持续至妊娠早期使用二甲双胍者临床妊娠率更高(OR 1.57,95%CI 1.11-2.23)。
- 与安慰剂或不治疗相比,持续使用二甲双胍者流产可能减少(OR 0.64,95%CI 0.32-1.25),活产可能增加(OR 1.24,95%CI 0.59-2.61)。
- 与安慰剂或不治疗相比,阳性妊娠试验后停用二甲双胍者临床妊娠率升高(OR 1.35,95%CI 1.01-1.80),流产率有升高迹象(OR 1.46,95%CI 0.73-2.90)。
- 持续使用至妊娠早期与阳性妊娠后停药的间接比较一致显示 favoring 持续使用的趋势:临床妊娠OR 1.16(95%CI 0.74-1.83),流产OR 0.44(95%CI 0.17-1.16),活产OR 1.14(95%CI 0.41-3.13)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 所有纳入研究质量分级为低至中等。
- 需要进一步的高质量研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to explore the effects of preconception and first-trimester metformin use on pregnancy outcomes in women with polycystic ovary syndrome. DATA SOURCES: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from database inception to August 1, 2024. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials of metformin started before conception and continued at least until a positive pregnancy test compared with either placebo or no treatment in women with polycystic ovary syndrome were included. METHODS: A systematic review and meta-analysis was conducted. Pooled odds ratios with 95% confidence intervals were calculated for the following key outcomes: miscarriage (primary) and clinical pregnancy and live birth (secondary). The studies were assessed for quality using the Cochrane risk-of-bias tool for randomized trials (RoB 2) and the Grading of Recommendations, Assessment, Development, and Evaluation approach. Indirect comparisons were performed for all key outcomes on the timing of metformin treatment using the Bucher technique. RESULTS: A total of 12 trustworthy studies (involving 1708 women) were included in the meta-analysis, all of which were graded low to moderate quality. Women who received preconception metformin that was continued throughout the first trimester of pregnancy showed higher clinical pregnancy rates (odds ratio, 1.57 [95% confidence interval, 1.11-2.23]), a possible reduction in miscarriage (odds ratio, 0.64 [95% confidence interval, 0.32-1.25]), and possible increase in live birth (odds ratio, 1.24 [95% confidence interval, 0.59-2.61]) than women who received either a placebo or no treatment. Women who stopped metformin once pregnant not only had an increase in clinical pregnancy rate (odds ratio, 1.35 [95% confidence interval, 1.01-1.80]) but also had an indication of an increase in miscarriage rate (odds ratio, 1.46 [95% confidence interval, 0.73-2.90]) compared with those who received a placebo or no treatment. Indirect comparisons between metformin continued through the first trimester of pregnancy and metformin stopped once pregnant consistently demonstrated a trend favoring the continuation of metformin: clinical pregnancy odds ratio of 1.16 (95% confidence interval, 0.74-1.83), miscarriage odds ratio of 0.44 (95% confidence interval, 0.17-1.16), and live birth odds ratio of 1.14 (95% confidence interval, 0.41-3.13). CONCLUSION: Continuing metformin treatment throughout the first trimester of pregnancy may reduce the risk of miscarriage and increase live birth rates in women with polycystic ovary syndrome. Continuation of metformin seems to have greater clinical benefit than discontinuation of metformin after a positive pregnancy test. There is a need for further high-quality research.
引用
- Cheshire J, Garg A, Smith P, et al. Preconception and first-trimester metformin on pregnancy outcomes in women with polycystic ovary syndrome: a systematic review and meta-analysis. Am J Obstet Gynecol. 2025. PMID: 40473092. doi:10.1016/j.ajog.2025.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。